BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

RemeGen Secures FDA Clearance for Phase II Trials of Innovative Bispecific Antibody RC148 in Advanced Solid Tumors

RemeGen Co., announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bisp...

August 11, 2025 | News

Mabwell’s CDH17-Targeting ADC 7MW4911 Receives IND Clearance in China and U.S.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug ...

August 04, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

Alphamab Oncology’s HER2-Targeting ADC JSKN003 Secures FDA Orphan Drug Designation for Gastric and GEJ Cancers

Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Foo...

July 29, 2025 | News

Biocytogen Expands Preclinical Capabilities Across Asia and the U.S. with Over 1,000 Humanized Mouse Models

Biocytogen (HKEX: 02315), an international biotechnology company that drives new drug development with innovative technologies, announced that its pr...

July 29, 2025 | News

China’s DualityBio Secures FDA Fast Track for Next-Gen HER3 ADC DB-1310 in Advanced Lung Cancer

DualityBio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting a...

July 23, 2025 | News

BioMed X and Servier Launch Europe’s First XSeed Labs at Paris-Saclay to Accelerate AI-Driven Bispecific Antibody Design

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced the launch of a new initiative with Se...

July 10, 2025 | News

InnoCare Pharma Receives IND Approval in China for Novel B7-H3 Targeted ADC ICP-B794

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the approval of the Inves...

July 07, 2025 | News

Akeso Doses First Patient in Phase Ia Trial of AK146D1, the World’s First Bispecific ADC Targeting Trop2 and Nectin4

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a...

July 04, 2025 | News

Daiichi Sankyo and AstraZeneca’s DATROWAY Receives U.S. FDA Accelerated Approval for EGFR-Mutated Lung Cancer

Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and ...

June 24, 2025 | News

LOTTE BIOLOGICS Expands Global CDMO Footprint with Antibody Therapeutics Deal with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and Europe LOTTE BIOLOGICS announced on June 19, 2025 that it ha...

June 19, 2025 | News

Veranova Invests Over $50M to Launch Bioconjugation Development and GMP Manufacturing in Massachusetts

Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for the pha...

June 19, 2025 | News

Debiopharm and Alkyon Therapeutics Join Forces to Advance Precision Radioligand Cancer Therapies

Research program combining Debiopharm’s AbYlink™ conjugation technology with Alkyon’s modular antibody platform and novel targeting app...

June 16, 2025 | News

Kelun-Biotech’s TROP2 ADC and PD-L1 Combo Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab ti...

June 12, 2025 | News

Stay Connected